Eisai (OTCPK:ESALY -0.4%) announces positive results from an open-label Phase 3 clinical trial in Japan and South Korea evaluating FYCOMPA (perampanel) CIII as monotherapy in new onset or untreated patients with partial-onset seizures. The data were presented at the International Epilepsy Congress in Bangkok.
63% (n=46/73) of treated patients with partial-onset seizures experienced seizure freedom at week 26. 65% (n=31/48) of patients with secondarily generalized seizures were convulsive seizure free.
The most common adverse events in 68 patients were dizziness (27%), nasopharyngitis (13%), somnolence (13%) and headache (10%).
FYCOMPA is approved in 55 countries.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.